A new report suggests that the global sterile injectable CDMO market is projected to reach $33.7 bn by 2034, driven by high demand for biologics, accelerated development timelines, and the shift towards end-to-end business models offering comprehensive services from API development to drug manufacturing.

“Pharmaceutical companies are relying on large-scale production and reliable supply chain management partners to gain a competitive edge in the industry,” says a lead analyst at Future Market Insights (FMI), the report’s authors.

Monoclonal antibodies lead the way, with a value share of 23.5% (in 2023), with North America considered the leading region for sterile injectables, with a value share of 36% (2023).

As per Future Market Insights (FMI)’ latest industry analysis, the global sterile injectable CDMO market was valued at around USD 10.1 billion in 2023 and is anticipated to exhibit a CAGR of 11.7% over the forecast period. The market value is projected to increase from USD 11.1 billion in 2024 to USD 33.7 billion by 2034.

The sterile injectable CDMO market is shifting towards an end-to-end business model, offering comprehensive services from API development to finished drug product manufacturing. This shift is driven by the high demand for accelerated development timelines and speed to market, especially in the biologics sector.

Leading CDMOs are escalating their integrated capabilities to provide seamless solutions, offering high cost flexibility and mitigating supply chain risks. The industry is also embracing standardized modularization to improve manufacturing efficiency and flexibility.

Increasing number of biologics in the pipeline and the trend of outsourcing are set to fuel growth in the market. Biopharmaceutical companies are expected to dominate the industry due to the rise in end-to-end outsourcing services, especially among small and mid-sized pharmaceutical companies lacking bulk capacity manufacturing expertise.

Key Takeaways from the Market Study:

• By manufacturing, the commercial manufacturing segment set to hold a lucrative share value of 57.2% in 2024.

• By services, the stand-alone segment is projected to hold the highest share of 61.1% in in terms of value in 2024.

• By drug type, monoclonal antibodies held a lucrative value share of 23.5% in 2023.

• By end-user, the pharmaceutical companies segment held a lucrative value share of 39.1% in 2023.

• North America is considered the leading region with a value share of 36.0% in 2023.

“The IV mode of application is gaining traction due to its rapid and precise treatment in emergency and hospital settings. Its growing demand for usage in intravenous drugs in chronic conditions is also pushing sales. Pharmaceutical companies are relying on large-scale production and reliable supply chain management partners to gain a competitive edge in the industry,” says a lead analyst at Future Market Insights (FMI).

For more, please find the original story source here.